Evidence map›Paper›PMID 12591902›Full record

ArticleThe Journal of experimental medicine2003

Selective activation of the c-Jun NH2-terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells.

Melissa R Snyder, Mathias Lucas, Eric Vivier, Cornelia M Weyand, Jörg J Goronzy

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Immune aging and autoimmunity.Cellular and molecular life sciences : CMLS · 2012
    Review
  8. Review
  9. Cytolytic CD4(+) T cells in viral immunity.Expert review of vaccines · 2010
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. T-cell co-stimulatory pathways in autoimmunity.Arthritis research & therapy · 2008
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Melissa R SnyderDepartment of Medicine/Rheumatology and Immunology, Mayo Clinic, Rochester, MN 55905, USA.
Mathias Lucas
Eric Vivier
Cornelia M Weyand
Jörg J Goronzy
Mayo Clinic in Arizona · USCentre d’Immunologie de Marseille-Luminy · FR

Funding

Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1993 to 2022
$4.8M
DIVERSITY OF T LYMPHOCYTES IN RHEUMATOID ARTHRITISR01AR041974 · NIAMS · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI GORONZY, JORG J. · 1994 to 2006
$2.1M
IMMUNOPATHWAYS IN ACUTE CORONARY SYNDROMESR01HL063919 · NHLBI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI WEYAND, CORNELIA M · 2001 to 2005
$1.8M
NHLBI NIH HHS R01 HL063919NHLBI NIH HHS R01 HL63919NIAMS NIH HHS R01 AR041974NIAMS NIH HHS R01 AR042527NIAMS NIH HHS R01 AR41974NIAMS NIH HHS R01 AR42527
6 · The paper itself

Abstract

Activation of CD4(+) T cells is governed by interplay between stimulatory and inhibitory receptors; predominance of stimulatory signals favors autoimmune reactions. In patients with rheumatoid arthritis, expression of the critical costimulatory molecule, CD28, is frequently lost. Instead, CD4(+)CD28(null) T cells express killer immunoglobulin-like receptors (KIRs) with a preferential expression of the stimulatory receptor, CD158j. The frequency of CD4(+)CD28(null) T cells in rheumatoid arthritis (RA) correlates with the risk for more severe disease. Moreover, the KIR2DS2 gene, which encodes for CD158j, is a genetic risk factor for rheumatoid vasculitis. CD158j signals through the adaptor molecule, KARAP/DAP12, to positively regulate cytotoxic activity in NK cells. However, the majority of CD4(+)CD28(null) T cell clones lacked the expression of KARAP/DAP12. Despite the absence of KARAP/DAP12, CD158j was functional and augmented interferon-gamma production after T cell receptor stimulation. Cross-linking of CD158j resulted in selective phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and its upstream kinase, MKK4 that led to the expression of ATF-2 and c-Jun, all in the absence of extracellular signal-regulated kinase (ERK)1/2 phosphorylation. Mutation of the lysine residue within the transmembrane domain of CD158j abolished JNK activation, suggesting that an alternate adaptor molecule was being used. CD4(+)CD28(null) T cells expressed DAP10 and inhibition of phosphatidylinositol 3-kinase, which acts downstream of DAP10, inhibited JNK activation; however, no interaction of DAP10 with CD158j could be detected. Our data suggest that CD158j in T cells functions as a costimulatory molecule through the JNK pathway independent of KARAP/DAP12 and DAP10. Costimulation by CD158j may contribute to the autoreactivity of CD4(+)CD28(null) T cells in RA.

Indexed as

MAP Kinase Kinase 4Adaptor Proteins, Signal TransducingBinding SitesCD4-Positive T-LymphocytesEnzyme ActivationHumansInterferon-gammaJNK Mitogen-Activated Protein KinasesJurkat CellsMembrane ProteinsMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesPhosphorylationProto-Oncogene Proteins c-junReceptors, Antigen, T-CellReceptors, ImmunologicAdaptor Proteins, Signal TransducingHCST protein, humanInterferon-gammaJNK Mitogen-Activated Protein KinasesMAP2K4 protein, humanMAP Kinase Kinase 4Membrane ProteinsMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesProto-Oncogene Proteins c-junReceptors, Antigen, T-CellReceptors, ImmunologicReceptors, KIRTYROBP protein, human

Identifiers

PMID12591902
PMCPMC2193867
OpenAlexW2097696241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.